1029 Vedere
BioCentury & Getty Images

Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal 

Vedere Bio II spins out with vision restoration and preservation programs

Novartis’ acquisition of Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and  give the Swiss pharma technology to deliver gene therapies to the retina intravitreally. 

Oct 30, 2020 | 12:52 AM GMT

Novartis’ acquisition of Atlas-incubated start-up Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and will give the Swiss pharma technology to deliver gene therapies to the

Read the full 954 word article

How to gain access

Continue reading with a
two-week free trial.